Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.71 USD | +2.40% | +1.79% | +6.88% |
28/03 | Reneo Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
25/03 | North American Morning Briefing : Tech in Focus on -2- | DJ |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|
Capitalization 1 | 208.8 | 57.15 | 53.3 | 57.15 | - |
Enterprise Value (EV) 1 | 61.15 | 57.15 | 53.3 | 57.15 | 57.15 |
P/E ratio | -3.9 x | -1.1 x | -0.63 x | -1.73 x | -3.29 x |
Yield | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - |
EV / Revenue | - | - | - | - | - |
EV / EBITDA | - | - | - | - | - |
EV / FCF | -56,18,689 x | - | - | - | - |
FCF Yield | -0% | - | - | - | - |
Price to Book | - | - | - | - | - |
Nbr of stocks (in thousands) | 24,424 | 24,530 | 33,312 | 33,421 | - |
Reference price 2 | 8.550 | 2.330 | 1.600 | 1.710 | 1.710 |
Announcement Date | 23/03/22 | 27/03/23 | 28/03/24 | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - |
EBIT 1 | - | -39.82 | -53.85 | -83.05 | -40.35 | -28.89 |
Operating Margin | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | - | -39.77 | -51.96 | -77.39 | -34.1 | - |
Net income 1 | -19.46 | -39.77 | -51.96 | -77.39 | -35.79 | -22.65 |
Net margin | - | - | - | - | - | - |
EPS 2 | -9.576 | -2.190 | -2.120 | -2.520 | -0.9900 | -0.5200 |
Free Cash Flow | - | -37.17 | - | - | - | - |
FCF margin | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share 2 | - | - | - | - | - | - |
Announcement Date | 19/03/21 | 23/03/22 | 27/03/23 | 28/03/24 | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | -12.75 | -10.62 | -13.02 | -12.43 | -13.84 | -14.56 | -16.12 | -21.04 | -20.89 | -25.01 | -17 | -8.728 | -7.712 | -6.904 |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -12.74 | -10.61 | -13.04 | -12.31 | -13.01 | -13.6 | -15.11 | -19.53 | -19.2 | -23.55 | -15.01 | -6.57 | -6.191 | -6.333 |
Net income 1 | -12.74 | -10.61 | -13.04 | -12.31 | -13.01 | -13.6 | -15.11 | -19.53 | -19.2 | -23.55 | -15.82 | -7.6 | -6.59 | -5.784 |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | -0.5200 | -0.3700 | -0.5300 | -0.5000 | -0.5300 | -0.5500 | -0.6000 | -0.6500 | -0.5700 | -0.7100 | -0.4333 | -0.1867 | -0.1700 | -0.1667 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 12/11/21 | 23/03/22 | 10/05/22 | 09/08/22 | 08/11/22 | 27/03/23 | 11/05/23 | 10/08/23 | 13/11/23 | 28/03/24 | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - |
Net Cash position | - | 148 | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - |
Free Cash Flow | - | -37.2 | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | -28% | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - |
Cash Flow per Share 2 | - | - | - | - | -1.170 | -0.4400 |
Capex | - | 0.2 | - | - | - | - |
Capex / Sales | - | - | - | - | - | - |
Announcement Date | 19/03/21 | 23/03/22 | 27/03/23 | 28/03/24 | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.88% | 57.15M | |
+0.67% | 42.4B | |
+44.30% | 40.04B | |
-6.20% | 28.31B | |
+6.55% | 24.94B | |
-21.66% | 18.96B | |
+29.96% | 12.3B | |
-1.57% | 11.95B | |
+16.03% | 11.32B | |
-4.80% | 11.55B |
- Stock Market
- Equities
- RPHM Stock
- Financials Reneo Pharmaceuticals, Inc.